nd have reduced some of the uncertainty and risk in a critical aspect of drug development. e Capital Markets And Industry Dynamics Are Favorable For New Investments & Exits: Since the most recent peak in fundraising in 2008, it has been estimated that the life sciences venture capital fundraising has contracted by 68%, f